JP2022545835A - 甲状腺眼症の治療方法 - Google Patents

甲状腺眼症の治療方法 Download PDF

Info

Publication number
JP2022545835A
JP2022545835A JP2022513569A JP2022513569A JP2022545835A JP 2022545835 A JP2022545835 A JP 2022545835A JP 2022513569 A JP2022513569 A JP 2022513569A JP 2022513569 A JP2022513569 A JP 2022513569A JP 2022545835 A JP2022545835 A JP 2022545835A
Authority
JP
Japan
Prior art keywords
igf
inhibitor
administered
ted
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513569A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545835A5 (enExample
Inventor
シャーマン ジェフリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Horizon Therapeutics Ireland DAC
Original Assignee
Horizon Therapeutics Ireland DAC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Therapeutics Ireland DAC filed Critical Horizon Therapeutics Ireland DAC
Publication of JP2022545835A publication Critical patent/JP2022545835A/ja
Publication of JP2022545835A5 publication Critical patent/JP2022545835A5/ja
Priority to JP2025101359A priority Critical patent/JP2025146837A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2022513569A 2019-08-28 2020-08-28 甲状腺眼症の治療方法 Pending JP2022545835A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025101359A JP2025146837A (ja) 2019-08-28 2025-06-17 甲状腺眼症の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962892849P 2019-08-28 2019-08-28
US62/892,849 2019-08-28
PCT/US2020/048350 WO2021041773A1 (en) 2019-08-28 2020-08-28 Methods for the treatment of thyroid eye disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025101359A Division JP2025146837A (ja) 2019-08-28 2025-06-17 甲状腺眼症の治療方法

Publications (2)

Publication Number Publication Date
JP2022545835A true JP2022545835A (ja) 2022-10-31
JP2022545835A5 JP2022545835A5 (enExample) 2023-09-05

Family

ID=74686009

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513569A Pending JP2022545835A (ja) 2019-08-28 2020-08-28 甲状腺眼症の治療方法
JP2025101359A Pending JP2025146837A (ja) 2019-08-28 2025-06-17 甲状腺眼症の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025101359A Pending JP2025146837A (ja) 2019-08-28 2025-06-17 甲状腺眼症の治療方法

Country Status (9)

Country Link
US (2) US20210253719A1 (enExample)
EP (1) EP4021500A4 (enExample)
JP (2) JP2022545835A (enExample)
CN (1) CN115175701A (enExample)
AU (1) AU2020337958A1 (enExample)
BR (1) BR112022003663A2 (enExample)
CA (1) CA3152740A1 (enExample)
CO (1) CO2022003582A2 (enExample)
WO (1) WO2021041773A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025015486A (ja) * 2023-07-18 2025-01-30 ホライゾン セラピューティクス アイルランド デジグネイテッド アクティビティ カンパニー 疾患の治療のためのｉｇｆ－１ｒの複素環式阻害剤

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022066A1 (en) 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
AU2018385766B2 (en) 2017-12-15 2022-12-01 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
WO2019173352A1 (en) 2018-03-05 2019-09-12 Hznp Limited Methods for the treatment of thyroid eye disease
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
AU2020337958A1 (en) 2019-08-28 2022-03-17 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease
CN113512116B (zh) * 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
US20220267450A1 (en) 2020-10-14 2022-08-25 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
CN113143928A (zh) * 2021-04-02 2021-07-23 苏州普乐康医药科技有限公司 一种osi-906的应用
EP4384219A4 (en) * 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
EP4395823A4 (en) * 2021-09-03 2025-07-16 Novarock Biotherapeutics Ltd BISPECIFIC BINDING PROTEINS THAT BIND TO CD137 AND A TUMOR-ASSOCIATED ANTIGEN
CA3256642A1 (en) * 2022-05-26 2023-11-30 Horizon Therapeutics Ireland Dac Methods and compositions for treatment of thyroid eye disease
WO2024069236A1 (en) * 2022-09-30 2024-04-04 Horizon Therapeutics Ireland Dac Methods for treating inactive or chronic thyroid eye disease
AU2024287547A1 (en) * 2023-07-07 2026-01-22 Viridian Therapeutics, Inc. Methods of treating chronic thyroid eye disease
WO2025051229A1 (zh) 2023-09-08 2025-03-13 北京拓界生物医药科技有限公司 Igf-1r及tshr结合蛋白及其医药用途
WO2025155888A1 (en) * 2024-01-19 2025-07-24 Sling Therapeutics, Inc. Use of inhibitors of insulin-like growth factor receptor-1 for ocular-associated disorders

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2373192A (en) 1943-03-13 1945-04-10 Walter M Lauer Antioxidants
US4567253A (en) 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US8153121B2 (en) 2000-10-06 2012-04-10 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
US8178304B2 (en) 2000-10-06 2012-05-15 Smith Terry J Diagnostic methods relating to Graves' disease and other autoimmune disorders
ME00502B (me) 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
CA2524305C (en) 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
WO2005058967A2 (en) 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
ES2426482T3 (es) 2005-01-27 2013-10-23 Kyowa Hakko Kirin Co., Ltd. Inhibidor de IGF-1R
DK1979001T3 (da) 2005-12-13 2012-07-16 Medimmune Ltd Bindingsproteiner, der er specifikke for insulinlignende vækstfaktorer og anvendelser deraf
ES2545907T3 (es) 2005-12-29 2015-09-16 Abbvie Inc. Inhibidores de proteína quinasa
AU2007245164A1 (en) 2006-03-28 2007-11-08 Biogen Idec Ma Inc. Anti-IGF-IR antibodies and uses thereof
EP2043651A2 (en) 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
HRP20140688T1 (hr) 2006-07-07 2014-10-24 Bristol-Myers Squibb Company Inhibitori piroltriazin kinaze
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
JP2010506941A (ja) 2006-10-17 2010-03-04 リセラ，インク． 甲状腺眼症の治療のための方法、組成物及び製剤
CN101932580B (zh) 2007-06-01 2013-05-22 葛兰素史密丝克莱恩有限责任公司 咪唑并吡啶激酶抑制剂
ES2424977T3 (es) 2007-08-08 2013-10-10 Glaxosmithkline Intellectual Property Development Limited Derivados de 2-[(2-{fenilamino}-1H-pirrolo[2,3-D]pirimidin-4-il)amino]benzamida como inhibidores de IGF-1R para el tratamiento del cáncer
CA2697612A1 (en) * 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-igf-1r antibodies and uses thereof
TW201211036A (en) 2010-06-17 2012-03-16 Kyowa Hakko Kirin Co Ltd Useful salts of indazole derivative
MX2013000617A (es) 2010-07-16 2013-06-13 Piramal Entpr Ltd Derivados sustituidos de imidazoquinolina como inhibidores de quinasa.
UY33539A (es) 2010-08-02 2012-02-29 Astrazeneca Ab Compuestos químicos alk
US8546443B2 (en) 2010-12-21 2013-10-01 Boehringer Ingelheim International Gmbh Benzylic oxindole pyrimidines
US8476409B2 (en) 2011-04-19 2013-07-02 Merrimack Pharmaceuticals, Inc. Bispecific anti-IGF-1R and anti-ErbB3 antibodies
AU2012245971A1 (en) 2011-04-21 2013-10-17 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013110585A1 (en) 2012-01-23 2013-08-01 Boehringer Ingelheim International Gmbh 5, 8 -dihydro- 6h- pyrazolo [3, 4 -h] quinazolines as igf-lr/lr inhibitors
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
WO2016064716A1 (en) 2014-10-20 2016-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination therapy of tshr antagonist and igfr inhibitor
JP6664414B2 (ja) 2015-05-13 2020-03-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＩＧＦ−１Ｒ／ＩＲ阻害薬としての新規５，８−ジメチル−９−フェニル−５，８−ジヒドロ−６Ｈ−ピラゾロ［３，４−ｈ］キナゾリン−２−イル）−（１Ｈ−ピラゾール−３−イル）−アミン及び誘導体
US20210284741A1 (en) * 2018-01-24 2021-09-16 Hznp Limited Methods for the treatment of thyroid eye disease
US11208489B2 (en) * 2018-01-24 2021-12-28 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease
US10457740B1 (en) * 2018-01-29 2019-10-29 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating cancer using P2RX2 inhibitors
WO2019173352A1 (en) 2018-03-05 2019-09-12 Hznp Limited Methods for the treatment of thyroid eye disease
AU2020337958A1 (en) 2019-08-28 2022-03-17 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AM J OPHTHALMOL, vol. 208, JPN6024031403, 1 August 2019 (2019-08-01), pages 281 - 288, ISSN: 0005690181 *
N ENGL J MED, vol. 376, no. 18, JPN6024031402, 2017, pages 1748 - 1761, ISSN: 0005690182 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025015486A (ja) * 2023-07-18 2025-01-30 ホライゾン セラピューティクス アイルランド デジグネイテッド アクティビティ カンパニー 疾患の治療のためのｉｇｆ－１ｒの複素環式阻害剤

Also Published As

Publication number Publication date
CA3152740A1 (en) 2021-03-04
US12600787B2 (en) 2026-04-14
WO2021041773A1 (en) 2021-03-04
EP4021500A4 (en) 2023-09-06
CO2022003582A2 (es) 2022-07-08
US20210253719A1 (en) 2021-08-19
US20220356257A1 (en) 2022-11-10
CN115175701A (zh) 2022-10-11
BR112022003663A2 (pt) 2022-05-24
AU2020337958A1 (en) 2022-03-17
JP2025146837A (ja) 2025-10-03
EP4021500A1 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
JP2022545835A (ja) 甲状腺眼症の治療方法
US12286481B2 (en) Methods for the treatment of thyroid eye disease
US12358993B2 (en) Methods for the treatment of thyroid eye disease
US20240301072A1 (en) Methods for the treatment of thyroid eye disease
JP2024510142A (ja) 甲状腺眼症の処置のための方法
US20250011417A1 (en) Methods for the treatment of thyroid eye disease
WO2025106642A1 (en) Methods for the treatment of thyroid eye disease
US20240109970A1 (en) Methods for treating inactive thyroid eye disease
KR20240171086A (ko) 위암의 치료
WO2024129468A1 (en) Methods for the treatment of noninfectious uveitis
TW202448947A (zh) 用satralizumab治療甲狀腺眼病
Saenz et al. Thyroid Eye Disease In Your Exam Lane: Whether managing associated side effects or referring and comanaging, you are integral to these patients' care teams.
PBO Adverse events included neutropenia, thrombocytopenia, elevated liver enzymes, and infections. These resolved with treatment and no patients needed to discontinue the drug due to an adverse event.
Fernandes Update on Graves’ ophthalmopathy
OPHTH CORRELATION OF CLINIC OBJECTIVE ASSESSME THYROID EY

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230828

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240606

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250617